LINC00930 and nasopharyngeal carcinoma: LINC00930, which was first reported in 2022 to be strongly up-regulated in the nasopharyngeal carcinoma(NPC), positively correlated with tumor stage and grade and associated with lymphatic invasion, metastasis, and poor prognosis [17].